🔗 Share this article

Following a hold-up and a particularly heated meeting, a federal vaccine advisory panel was expected to vote on Friday concerning altering the enduring advisory that every infant be inoculated against hepatitis B.

Intense Discussion and a Delayed Ballot

The opening session of the assembly on Thursday was characterized by intense argument over curbing eligibility to the hepatitis B vaccine for babies and a decision to defer the vote by a day to allow panelists additional time to scrutinize the phrasing. The committee, which advises the national health agency on vaccine use, had put off the vote twice in the past.

“Is there any definitive data of harm of giving this immunization before 30 days? Or is this conjecture?” questioned one panel member.

In answer, another attendee stated, “There is inadequate data about the enduring danger.”

Present Protocol and Possible Consequences

The shot is presently advised for every newborn within 24 hours of being born to halt contraction of hepatitis B, which can cause serious liver damage. It has been given to 1.4 billion people for over thirty years.

The Atlanta conference provided no recent proof of damage attributable to the vaccine. Specialists note any alteration to the present hepatitis B vaccine regimen could have profound and widespread consequences for childhood health in the United States.

Panel Composition and Recent Changes

The expert committee can only make recommendations to the head of the CDC. The committee's composition has experienced alterations this week, with the declaration that the panel's latest chairman would depart for an official role and be replaced by a cardiologist who has been questioning of other immunizations.

The committee includes a number of vaccine skeptics who support a goal to reform – and possibly, in some cases, scrap – traditional immunization guidelines.